Carbocalcitonin (Turbocalcin* * Carbocalcitonin - Turbocalcin: ISF, Italy.) treatment of Paget's disease and osteoporosis. Preliminary results

G. Mantovani, U. Pastore, E. Varriale, P. Cerea, M. Ulivi, G. Bonfiglio, G. Torri, V. Pietrogrande

Research output: Contribution to journalArticlepeer-review

Abstract

A study of Paget's disease patients, classed as non-responders to other calcitonins, and of high-turnover osteoporotic patients is presented. In these two groups of patients evaluation was made of the clinical and metabolic changes produced by carbocalcitonin therapy over a relatively short time period, corresponding to 30 days in the case of Paget's disease patients and 60 days in the case of osteoporotic patients. After treatment with 40 units of carbocalcitonin the changes observed in alkaline phosphatase and urinary hydroxyproline respectively are described. Trends of different significance were observed for Paget's disease patients and osteoporotic patients. The pain parameter showed positive changes in both groups. Different pathogenic hypotheses are postulated in the light of these results.

Original languageEnglish
Pages (from-to)109-117
Number of pages9
JournalClinical Trials Journal
Volume23
Issue numberSUPPL. 1
Publication statusPublished - 1986

Keywords

  • alkaline phosphatase
  • carbocalcitonin
  • osteoporosis
  • Paget's bone disease
  • urinary hydroxyproline

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Carbocalcitonin (Turbocalcin* * Carbocalcitonin - Turbocalcin: ISF, Italy.) treatment of Paget's disease and osteoporosis. Preliminary results'. Together they form a unique fingerprint.

Cite this